Antiplatelet agents in tissue factor-induced blood coagulation

Blood

Volumn 97, Issue 8, 2001, Pages 2314-2322

  Butenas, Saulius ^a   Cawthern, Kevin M ^a   Van't Veer, Cornelis ^a   DiLorenzo, Maria E ^a   Lock, Jennifer B ^a   Mann, Kenneth G ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; DIPYRIDAMOLE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR AFFECTING AGENT; FIBRINOPEPTIDE A; PROSTAGLANDIN E1; THROMBIN; THROMBIN ANTITHROMBIN COMPLEX; THROMBOPLASTIN;

ARTICLE; ATTENUATION; BLOOD CLOTTING; BLOOD CLOTTING TIME; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOASSAY; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION;

EID: 0035871811     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.8.2314     Document Type: Article

References (51)

1. Antiplatelet therapy: Properties of platelets
2. Platelet morphology, biochemistry and function
3. The pathogenesis of coronary artery disease and the acute coronary syndromes (1)
4. The pathogenesis of coronary artery disease and the acute coronary syndromes (2)
5. Pathogenesis of thrombosis
6. Evaluation of the initiation phase of blood coagulation using ultrasensitive assays for serine proteases
7. Blood clotting in minimally altered whole blood
8. Platelet morphology
9. Generation of prothrombin converting activity and the exposure of phosphatidylserine at the outer surface of platelets
10. Transbilayer movement of phospholipids in red cell and platelet membranes
11. Pathophysiologic implications of membrane phospholipid asymmetry in brood cells
12. Mechanisms of platelet activation
13. The coagulation cascade: Initiation, maintenance and regulation
14. The tissue factor pathway: How it has become a 'prima ballerina.'
15. Surface-dependent hemostasis
16. Coagulation cascade: An overview
17. In situ-generated thrombin is the only enzyme that effectively activates factor VIII and factor V in thromboplastin-activated plasma
18. Fibrinogen and fibrin - Proteins with complex roles in hemostasis and thrombosis
19. Fibrinogen and fibrin
20. The haemostatic plug in haemophilia A: A morphological study of haemostatic plug formation in bleeding time skin wounds of patients with severe haemophilia A
21. Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular cells
22. Recombinant tumor necrosis factor induces procoagulant activity in cultured human endothelium: Characterization and comparison with the actions of interleukin 1
23. Inducible endothelial functions in inflammation and coagulation
24. Aspirin as an antiplatelet drug
25. Inhibition of prostaglandins as a mechanism of action for aspirin-like drugs
26. Thromboxane A2 in skin-bleeding-time blood and in clotted venous blood before and after administration of acetylsalicylic acid
27. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects
28. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa
29. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty: The EPIC investigation
30. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
31. Randomized placebo-controlled trial of abciximab before and during coronary intervention on refractory unstable angina: The CAPTURE study
32. Effects of Integrilin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina: A multicenter trial
33. The IMPACT-II Investigators Randomized placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention IMPACT-II
34. Blood coagulation in hemophilia A and hemophilia C
35. 2Cl-A selective affinity label for thrombin
36. Hageman factor fragment inhibitor in corn seeds: Purification and characterization
37. A simple method for the preparation of homogeneous phospholipid vesicles
38. Activation of factor IX by the reaction product of tissue factor and factor VII: Additional pathway for initiating blood coagulation
39. The effect of thrombocytopenia on the tissue factor pathway
40. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation
41. Antiplatelet drugs
42. Orally active prestacyclin analogue in primary pulmonary hypertension
43. Dipyridamole
44. A model for the tissue factor pathway to thrombin; I: An empirical study
45. Regulation of tissue factor initiated thrombin generation by the stoichiometric inhibitors tissue factor pathway inhibitor, antithrombin-III, and heparin colactor-II
46. A model for the tissue factor pathway to thrombin, II: A mathematical simulation
47. The effect of active site-inhibited factor VIIa on tissue factorinitiated coagulation using platelets before and after aspirin administration
48. Inhibition of platelet mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody: Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis."
49. Potential role of abciximab in ischemic cerebrovascular disease
50. Diffuse alveolar hemorrhage following administration of tirofiban or abciximab: A nemesis of platelet glycoprotein Iib/IIIa inhibitors
51. Fatal cerebral hemorrhage and severe thrombocytopenia during abciximab treatment